Expression of MMP-9 in different degrees of chronic hepatitis B and its correlation with inflammation

Li,Yujuan; Liu,Hongtao; Xu,Lixiu

doi:10.3892/etm.2018.6673

Expression of MMP-9 in different degrees of chronic hepatitis B and its correlation with inflammation

Authors:
- Yujuan Li
- Hongtao Liu
- Lixiu Xu
View Affiliations

Affiliations: Laboratory Department, Dongying People's Hospital, Dongying, Shandong 257091, P.R. China
Published online on: August 31, 2018 https://doi.org/10.3892/etm.2018.6673
Pages: 4136-4140
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of matrix metalloproteinase-9 (MMP-9) in different degrees of chronic hepatitis B (CHB) and the correlation of MMP-9 with inflammation was investigated. A total of 96 CHB patients (observation group) admitted and treated in Dongying People's Hospital from December 2016 to November 2017 were selected, and they were compared with 60 healthy individuals (control group) selected in the physical examination center during the same time period. Enzyme‑linked immunosorbent assay (ELISA) was used to detect the expression of MMP-9, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), MMP-9 expression in different inflammation grades and fibrosis stages, and the relationship between MMP-9 and inflammation was analyzed. The levels of MMP-9, TNF-α and IL-6 in serum in the observation group were obviously higher than those in the control group (P<0.05). The rank sum test indicated that there were statistically significant differences in the expression levels of MMP-9 among the inflammation grades G0, G1, G2, G3 and G4 (P<0.05). The expression levels of MMP-9 in fibrosis stages S0, S1, S2, S3 and S4 were detected via the rank sum test, and it suggested that the differences among the 5 stages were statistically significant (P<0.05). Pearson's correlation analysis showed that the MMP-9 expression level was positively correlated with TNF-α and IL-6 (P<0.05). In conclusion, the MMP-9 level is elevated remarkably in patients with varying degrees of CHB, it may play an important role in the pathological progress of liver, and it has a close correlation with inflammation, which can provide a theoretical basis for clinical treatment.

View Figures

View References

1	Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, et al: Towards an HBV cure: State-of-the-art and unresolved questions - report of the ANRS workshop on HBV cure. Gut. 64:1314–1326. 2015. View Article : Google Scholar : PubMed/NCBI
2	MacLachlan JH and Cowie BC: Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 5:a0214102015. View Article : Google Scholar : PubMed/NCBI
3	Roberts H, Kruszon-Moran D, Ly KN, Hughes E, Iqbal K, Jiles RB and Holmberg SD: Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988–2012. Hepatology. 63:388–397. 2016. View Article : Google Scholar : PubMed/NCBI
4	Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R, et al: Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology. 62:79–86. 2015. View Article : Google Scholar : PubMed/NCBI
5	Lamb C and Arbuthnot P: Activating the innate immune response to counter chronic hepatitis B virus infection. Expert Opin Biol Ther. 16:1517–1527. 2016. View Article : Google Scholar : PubMed/NCBI
6	Jakubowska K, Pryczynicz A, Iwanowicz P, Niewiński A, Maciorkowska E, Hapanowicz J, Jagodzińska D, Kemona A and Guzińska-Ustymowicz K: Expressions of matrix metalloproteinases (MMP-2, MMP-7, and MMP-9) and their inhibitors (TIMP-1, TIMP-2) in inflammatory bowel diseases. Gastroenterol Res Pract. 2016:24561792016. View Article : Google Scholar : PubMed/NCBI
7	Nguyen K, Pan C, Xia V, Hu J and Hu KQ: Clinical course of chronic hepatitis B (CHB) presented with normal ALT in Asian American patients. J Viral Hepat. 22:809–816. 2015. View Article : Google Scholar : PubMed/NCBI
8	Bae CB, Kim SS, Ahn SJ, Cho HJ, Kim SR, Park SY, Song GW, Kim DJ, Hwang SG, Yang JM, et al: Caspase-cleaved fragments of cytokeratin-18 as a marker of inflammatory activity in chronic hepatitis B virus infection. J Clin Virol. 58:641–646. 2013. View Article : Google Scholar : PubMed/NCBI
9	Himaja N and Shama SN: Herbal wealth for hepatotoxicity: A review. ASIA J Pharm Sci. 8:3–9. 2015.
10	Price J: An update on hepatitis B, D, and E viruses. Top Antivir Med. 21:157–163. 2014.PubMed/NCBI
11	Ofliver KA: Korean Association for the Study of the Liver: KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 18:109–162. 2012. View Article : Google Scholar : PubMed/NCBI
12	Karev VE: Fas, FasL, and bcl-2 expression on hepatic intralobar lymphocytes in different variants of the natural course of chronic HBV and HCV infection and in its outcomes. Arkh Patol. 76:16–21. 2014.(In Russian). PubMed/NCBI
13	Peng CY, Hsieh TC, Hsieh TY, Tseng KC, Lin CL, Su TH, Tseng TC, Lin HH, Wang CC and Kao JH: HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients. J Formos Med Assoc. 114:308–313. 2015. View Article : Google Scholar : PubMed/NCBI
14	Tsamandas AC, Thomopoulos K, Zolota V, Kourelis T, Karatzas T, Ravazoula P, Tepetes K, Petsas T, Karavias D, Karatza C, et al: Potential role of bcl-2 and bax mRNA and protein expression in chronic hepatitis type B and C: A clinicopathologic study. Mod Pathol. 16:1273–1288. 2003. View Article : Google Scholar : PubMed/NCBI
15	Coffin CS, Osiowy C, Gao S, Nishikawa S, van der Meer F and van Marle G: Hepatitis B virus (HBV) variants fluctuate in paired plasma and peripheral blood mononuclear cells among patient cohorts during different chronic hepatitis B (CHB) disease phases. J Viral Hepat. 22:416–426. 2015. View Article : Google Scholar : PubMed/NCBI
16	Aoudjit F, Estève PO, Desrosiers M, Potworowski EF and St-Pierre Y: Gelatinase B (MMP-9) production and expression by stromal cells in the normal and adult thymus and experimental thymic lymphoma. Int J Cancer. 71:71–78. 1997. View Article : Google Scholar : PubMed/NCBI
17	Chen J, Xu W, Chen Y, Xie X, Zhang Y, Ma C, Yang Q, Han Y, Zhu C, Xiong Y, et al: MMP-9 facilitates hepatitis B virus replication through binding with IFNAR1 to repress IFN/JAK/STAT signaling. J Virol. 91:e01824–16. 2017. View Article : Google Scholar : PubMed/NCBI
18	Zhao ZH, Fan YC, Zhao Q, Dou CY, Ji XF, Zhao J, Gao S, Li XY and Wang K: Promoter methylation status and expression of PPAR-γ gene are associated with prognosis of acute-on-chronic hepatitis B liver failure. Clin Epigenetics. 7:1152015. View Article : Google Scholar : PubMed/NCBI
19	De Simone V, Franzè E, Ronchetti G, Colantoni A, Fantini MC, Di Fusco D, Sica GS, Sileri P, MacDonald TT, Pallone F, et al: Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-κB to promote colorectal cancer cell growth. Oncogene. 34:3493–3503. 2015. View Article : Google Scholar : PubMed/NCBI
20	Somal A, Aggarwal A and Upadhyay RC: Effect of thermal stress on expression profile of apoptosis related genes in peripheral blood mononuclear cells of transition Sahiwal cow. Iran J Vet Res. 16:137–143. 2015.PubMed/NCBI